Published • loading... • Updated
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
- The ELEVATE study of Betta Pharmaceuticals' ensartinib as postoperative adjuvant therapy for stage IB-IIIB ALK-positive non-small cell lung cancer was published online in The New England Journal of Medicine on July 8.
- In the ELEVATE study, 274 patients from 56 medical centers in China were randomized to receive either oral ensartinib or placebo after surgery and any planned chemotherapy.
- The study showed a 2-year disease-free survival rate of 86.4% with ensartinib versus 53.5% with placebo, with a hazard ratio of 0.20 in patients with stage II to IIIB non-small cell lung cancer.
- Two years of adjuvant ensartinib treatment reduces the risk of disease recurrence or death by 80% according to the study results.
Insights by Ground AI
42 Articles
42 Articles
Bennington Banner+41 Reposted by 41 other sources
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
HANGZHOU, China, July 8, 2026 /PRNewswire/ -- On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, was published online in…
Coverage Details
Total News Sources42
Leaning Left5Leaning Right5Center25Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
